Safety Evaluation of Bilateral Same-day Intravitreal Ranibizumab Injections
안자영, 장규환, 손준홍, 황덕진,
소속 상세정보
안자영 ( Ahn Ja-Young )
HanGil Eye Hospital
장규환 ( Jang Kyu-Hwan )
HanGil Eye Hospital
손준홍 ( Sohn Joon-Hong )
HanGil Eye Hospital
황덕진 ( Hwang Duck-Jin )
HanGil Eye Hospital
KMID : 1038920200190030061
Abstract
Purpose: This study aimed to evaluate the safety of bilateral same-day intravitreal ranibizumab injections by analyzing ophthalmic complications.
Methods: Medical records of patients who underwent bilateral same-day intravitreal ranibizumab injections between January 2016 and December 2018 were retrospectively reviewed. Patient follow-up visits occurred 1 day, 1 month, and 2 months after the injections.
Results: The study included a total of 31 patients, 62 eyes, and 148 bilateral same-day intravitreal ranibizumab injections. The most frequent cause for treatment was exudative age-related macular degeneration, totaling 126 injections (85.1%). Diabetic macular edema accounted for 20 injections (13.5%), and macular edema due to retinal vein occlusion accounted for two injections (1.4%). There were no cases of endophthalmitis, retinal detachment, or vitreous hemorrhage in any patient. We observed five eyes (3.38%) with sterile inflammation, of which three improved without any treatment. The remaining two eyes were in a single patient, and the inflammation improved after four days of treatment. Four eyes (2.7%) exhibited vitreous floaters, and subconjunctival hemorrhage was observed in five eyes (3.38%).
Conclusions: The ocular complication rate of bilateral same-day intravitreal ranibizumab injection procedure was low.
키워드
Bilateral; Endophthalmitis; Intravitreal injection; Ranibizumab; Sterile inflammation
원문 및 링크아웃 정보
등재저널 정보